state healthcar impact
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim jun
price data jul
rate updat jul
currenc amount express
methodolog valu compani
despit mani australian-list healthcar stock cover
substanti revenu exposur latest
potenti regulatori chang market pose low risk
fair valu estim cost access
healthcar emot topic among voter henc
forefront polit agenda relev
australian compani oper draft
lower health cost act lhcca aim
improv transpar healthcar sector reduc
prescript drug price well presid donald
trump recent execut order transpar
comment cap drug price lowest developed-
australian-list healthcar compani
revenu stream decreas order contribut
report estim mayn pharma
fisher paykel cochlear sonic
healthcar howev revenu risk
price medic devic suppli public health
like fisher paykel cochlear
price diagnost servic provid sonic healthcar
alreadi subject regulatori price action
past year result signific price
pressur devic diagnost like behind us
result focu squar drug price narrow-
moat no-moat mayn pharma expos new
regulatori chang howev quantifi potenti
revenu loss less compani
limit revenu impact result low downsid risk
fair valu estim aud aud
mayn pharma maintain compani
 key market mesoblast research
develop pipelin howev perceiv low
risk price assumpt closest market
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
one largest global respiratori medic devic compani
primarili develop suppli flow gener mask accessori
treatment sleep apnea increas diagnosi sleep apnea
combin age popul increas preval obes
result structur grow market compani earn
revenu america balanc across region domin
europ japan australia recent develop acquisit
focus digit health aim differenti
provis clinic data use patient medic care advisor
payor out-of-hospit set
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
product includ fair valu estim aud
leav valuat unchang stage
chang price drug necessarili feed
back directli manufactur know list price
brand drug higher averag
european develop countri benchmark
conclus reach comparison
 intern price top medicar part drug
total expenditur publish depart
human servic octob howev
market extrem opaqu link list
price revenu pharma compani receiv
cost patient directli relat
role play pharmaci benefit manag pbm
collect rebat manufactur pass
patient withdraw propos
rebat rule would requir full pass
rebat commun juli leav
intern price index propos next
consider lower cost drug
estim less loss revenu
intern price index propos implement
propos target physician-administ pharmacy-
dispens self-administ drug suppli medicar
refer part drug base sale includ
studi depart human servic
estim approxim group
revenu studi includ csl privigen intraven
immunoglobulin ivig product comparison
ex-manufactur price part
categori drug conclud price
similar defin within intern
price per gram basi outcom conclud
competitor grifol ivig product gamunex-c grifol
gammagard rate lower price
downward price adjust csl part product would
result loss revenu group total
biosimilar also refer lhcca threat
csl plasma product high barrier entri
industri rather patent limit competit
despit earn revenu
estim less possibl loss revenu mayn
pharma implement compani earn
vast major revenu gener product market
price alreadi recent
year revenu brand product
portion may part basket brand
drug distribut mayn pharma exclus
period therefor unlik command major price
premium downward price revis half
brand basket group sale would result
revenu loss result implement
propos would signific impact aud
fair valu estim compani
mesoblast doesnt current earn revenu
howev closest market pipelin product current
fda biolog licens approv process price
estim potenti therapi base competitor
product market lower
equival product japan countri
regist nonetheless major focu
compani drug price reform could pose risk
valuat mesoblast pipelin adjust fair
valu estim stage
healthcare-rel bill current
congress uncertainti law ultim
pass view morningstar healthcar
strategist karen andersen equiti analyst jake strole
unlik implement detail
report juli rebat rule dead suppli chain
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
benefit drug firm pressur instead expect drug
price reform part medicar product could take
differ form possibl cap out-of-pocket
payment self-administ prescript drug
natur revenu earn mayn pharma
 result low exposur type drug price
reform limit impact fair valu estim
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end june
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end june
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
